Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PHAXIAM Therapeutics's enterprise value is $0.00 Mil.
PHAXIAM Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.56 Mil. Therefore, PHAXIAM Therapeutics's EV-to-EBITDA for today is -0.00.
The historical rank and industry rank for PHAXIAM Therapeutics's EV-to-EBITDA or its related term are showing as below:
PXMTF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 13.485 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PHAXIAM Therapeutics's PE Ratio (TTM) for today is calculated as:
PHAXIAM Therapeutics's share price for today is $0.0001.
PHAXIAM Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.949.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PHAXIAM Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PXMTF vs VRTX, REGN, SGEN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, PHAXIAM Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PHAXIAM Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PHAXIAM Therapeutics's EV-to-EBITDA falls into.
PHAXIAM Therapeutics's current Enterprise Value is $0.00 Mil.
PHAXIAM Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAXIAM Therapeutics (PXMTF) has a EV-to-EBITDA of -0.00 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PHAXIAM Therapeutics.
Is PHAXIAM Therapeutics' EV-to-EBITDA too high?
PHAXIAM Therapeutics' current EV-to-EBITDA is -0.00. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
PHAXIAM Therapeutics' EV-to-EBITDA of -0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PHAXIAM Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PHAXIAM Therapeutics's current EV-to-EBITDA is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current EV-to-EBITDA of -0.00. The current EV-to-EBITDA is -0.00. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current EV-to-EBITDA is -0.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score
Get the complete analysis for PXMTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMTF has been successfully added to your 
